- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05180851
A Clinical Study of Recombinant Oncolytic Adenovirus L-IFN Injection With Multiple Administration Routes in Relapsed/Refractory Solid Tumors (YSCH-01)
Bezpieczeństwo i skuteczność iniekcji rekombinowanego adenowirusa L-IFN w leczeniu nawrotowych/opornych na leczenie guzów litych: jedno/wieloośrodkowe, rozszerzające kohortę badanie kliniczne ze zwiększaniem dawki
This is an open-label, dose-escalation study evaluating the safety and tolerability of Recombinant Oncolytic Adenovirus L-IFN Injection (YSCH-01) administered via different routes, including intratumoral injection and aerosol therapy, in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of Recombinant L-IFN adenovirus injection
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This is an investigator-initiated, open-label study evaluating Recombinant Oncolytic Adenovirus L-IFN Injection as a single agent administered via different routes, including intratumoral (IT) injection and aerosol therapy, in participants with advanced solid tumors.The study is a single agent dose escalation which will use a 3+3 design to evaluate escalating doses of Recombinant L-IFN adenovirus injection. Total enrollment will depend on the toxicities and/or activity observed, with approximately19-28 evaluable participants enrolled.
The primary study objective is to determine the safety, tolerability, and maximum tolerated dose (MTD) of intratumoral administration of Recombinant oncolytic adenovirus L-IFN injection as a single agent. Secondary objectives will assess efficacy overall response rate, as well as disease control rate, progression free survival, duration of response, and anti-tumor immune responses.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Wczesna faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chiny, 201406
- Shanghai Fengxian District Central Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male or female aged ≥ 18 and ≤ 75 years;
- Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who have failed standard therapy, have no standard therapy, are not eligible for standard therapy at this stage, or have refused standard therapy;
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the length of non-lymph node lesion ≥10 mm or the short diameter of lymph node lesion ≥15 mm according to CT or MRI cross-sectional images;CT scan of the longest axis of measurable lesions ≥10 mm (CT scan thickness ≤5 mm);
- There were injectable tumor lesions that met the requirements of the current dose group, including superficial lesions and deep lesions that could be injected under the guidance of B-ultrasound /CT;
- ECOG score of 0 ~ 2;
- Sufficient hematopoietic capacity: ANC ≥1.0 ×10^9/L (no short-acting albino within 1 week, no long-acting albino within 2 weeks), platelet count ≥75 ×10^9/L, HGB > 80 g/L (no blood transfusion within 2 weeks);
- Adequate liver and kidney function: AST and ALT ≤3 times ULN in patients without liver metastasis, ≤5 times ULN in patients with liver metastasis; Total bilirubin ≤1.5 ULN (excluding hyperbilirubinemia or hyperbilirubin of non-liver origin);Creatinine ≤2.0 ULN and creatinine clearance and creatinine clearance ≥40 mL/min;
- Eligible and fertile patients (male and female) must agree to use a reliable contraceptive method during the trial and for at least 90 days after the last dose; Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting treatment;
- PT or INR <1.5 ULN, and APTT <1.5 ULN;
- Expect to live at least 12 weeks;
Exclusion Criteria:
-
Received any antineoplastic therapy within 2 weeks prior to initial treatment;
-
Systemic diseases that have not been stably controlled after treatment, such as diabetes, serious organic cardiovascular and cerebrovascular diseases, cardiac insufficiency, hypertension, heart block above ⅱ degree, myocardial infarction within 6 months, cerebral infarction within 6 months, etc.
-
Pregnancy or lactation;
-
Uncontrolled infectious diseases, such as baseline HBV DNA≥2000 IU/ml, anti-HIV positive, HCV-RNA positive;
-
Other active infections of significant clinical significance;
-
Subjects with other active malignancies within the past 5 years, such as basal or squamous skin cancer, superficial bladder cancer, or breast cancer in situ, that have been completely cured and do not require follow-up treatment are excluded;
-
Severe autoimmune diseases such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, autoimmune vasculitis, or Wegener's granuloma require long-term (more than 2 months) systemic immunosuppressive therapy, but subjects with the following conditions are admitted:
Autoimmune hypothyroidism requiring only hormone replacement therapy; Skin disorders that do not require systemic treatment (e.g., eczema, a rash of less than 10% of the body surface);
-
Subjects with allergic constitution, allergy to immunotherapy or related drugs;
-
Organ failure; Coronary heart: grades ⅲ and ⅳ;Or hypertension that cannot be controlled by standard treatment, a history of myocarditis or myocardial infarction within one year; Gallo liver: achieves grade C on the Child-Turcotte-Pugh liver function scale; Gallonic kidney: renal failure and uremia; Lung: symptoms of severe respiratory failure; Brain unconsciously: people with consciousness disorder have active brain metastases;
-
Patients with active bleeding and thrombotic diseases requiring treatment;
-
Patients with uncontrollable pleural and abdominal effusion requiring clinical treatment or intervention;
-
Subjects requiring systemic corticosteroids (equivalent to >10 mg prednisone/day) within 14 days prior to enrollment or during the study period;
The following conditions are allowed to join the group:
Allow subjects to use topical or inhaled corticosteroids; Allows short-term (≤7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases;
-
Subject suffering from any mental illness, including dementia, altered mental state, that may affect informed consent and understanding of the relevant questionnaire;
-
Participated in clinical trials of other drugs or medical devices within 4 weeks;
-
If the investigator determines that they have a serious and uncontrollable disease or other conditions that may affect their acceptance of this study, they are not considered suitable for this study.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Safety and efficacy of recombinant L-IFN adenovirus injection in relapsed/refractory solid tumors
1.Only 1 lesion: If the tumor volume is less than or equal to 10 cm3, the whole tumor is injected radially and evenly. If the tumor volume was >10 cm3, the tumor was evenly divided into five quadrants and injected into one quadrant at a time. 2. If there are 2 or more lesions, the most manageable tumor injection is selected; 3. Priority should be given to the body surface metastases that meet the evaluation criteria for tumor efficacy. 4. According to patients' conditions (e.g., patients with thorax and ascites), the investigator and the research group and cooperative units jointly explored other drug administration approaches (e.g., bladder infusion, thorax and abdominal cavity administration,aerosol therapy) |
Intratumoral injection: Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly. Aerosol therapy: Recombinant Oncolytic Adenovirus L-IFN Injection is delivered to participants via inhalation using a nebulization device.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Dose Limiting Toxicities (DLT)
Ramy czasowe: Up to 28 days
|
To define the maximum tolerated dose (MTD) of intratumoral administration of Recombinant L-IFN adenovirus injection in humans with malignant tumors. |
Up to 28 days
|
|
Safety and tolerability assessed by Adverse Events (AEs)
Ramy czasowe: Time Frame: Up to 6 months
|
An AE is any untoward medical occurrence in a subject administered an investigational product (IP), and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP whether or not considered related to the IP |
Time Frame: Up to 6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of participants with vital sign abnormalities and /or adverse event
Ramy czasowe: Up to 6 months
|
Number of participants with potentially clinically significant laboratory values |
Up to 6 months
|
|
Number of participants with laboratory value abnormalities and/or adverse events
Ramy czasowe: Up to 6 months
|
Number of participants with potentially clinically significant laboratory values |
Up to 6 months
|
|
Presence of neutralizing antibodies of antidrug antibodies (ADAs) development
Ramy czasowe: Up to 6 months
|
To evaluate the immunogenicity of Recombinant L-IFN adenovirus injection given as single agent post injection |
Up to 6 months
|
Współpracownicy i badacze
Współpracownicy
Śledczy
- Główny śledczy: Feng Liu, PhD, Shanghai Fengxian District Central Hospital
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby układu hormonalnego
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Infekcje
- Choroby Układu Oddechowego
- Nowotwory według typu histologicznego
- Choroby macicy
- Choroby narządów płciowych, kobiety
- Choroby płuc
- Nowotwory gruczołów dokrewnych
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Choroby jajników
- Choroby przydatków
- Nowotwory narządów płciowych, kobiety
- Zaburzenia gonad
- Choroby skórne
- Choroby piersi
- Nowotwory urologiczne
- Choroby szyjki macicy
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Nowotwory macicy
- Guzy neuroendokrynne
- Nevi i czerniaki
- Nowotwory skóry
- Choroby Pęcherza Moczowego
- Choroby skóry i tkanki łącznej
- Nowotwory płuc
- Nowotwory jajnika
- Nowotwory piersi
- Nowotwory szyjki macicy
- Nowotwory głowy i szyi
- Czerniak
- Nowotwory pęcherza moczowego
- Choroby wirusowe
- Lecznictwo
- Terapia biologiczna
- Wirutoterapia onkolityczna
Inne numery identyfikacyjne badania
- YSCH-01-0000
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .